FDA Seeks Approval for Emergency Drug Authorization Forms
Published Date: 11/24/2025
Notice
Summary
The FDA is asking for public feedback on their paperwork for emergency use authorizations (EUAs) of medical products, like vaccines or treatments used during health emergencies. This helps keep the process smooth and up-to-date without adding extra costs or delays. Comments are open until December 24, 2025, so anyone involved in medical product development or emergency response should take note!
Analyzed Economic Effects
6 provisions identified: 1 benefits, 5 costs, 0 mixed.
Recordkeeping Burden for EUA Holders
EUA holders must keep records under conditions of authorization; FDA estimates annual recordkeeping of 35,200 hours for EUA holders. The tables in the notice also report an overall recordkeeping total shown as 59,403 hours (including state and local entries), reflecting the paperwork time tied to maintaining required records.
EUA Application Reporting Burden
If you apply for an Emergency Use Authorization (EUA) or a substantive amendment, FDA estimates a total annual reporting burden of 6,435 hours across respondents for those requests. The estimate covers submissions to CBER, CDER, and CDRH and reflects the paperwork time required to request an EUA or amend an existing EUA.
Required Dissemination and Disclosure Burden
EUA holders and authorized stakeholders must disseminate required information (fact sheets, advertising, promotional materials); FDA estimates an annual third‑party disclosure burden of 6,920 hours for these activities. The estimate covers preparing and distributing required fact sheets and related informational materials.
Net Reduction in Paperwork Burden
FDA reports the estimated information collection burden reflects an overall decrease of 7,087 hours and a decrease of 302,456 responses compared to prior estimates. That reduction lowers the total paperwork burden for respondents covered by this collection.
Pre‑EUA Submission Time Burden
If you submit a pre‑EUA package (information for FDA review before an EUA), FDA estimates a total annual burden of 1,292 hours across respondents for pre‑EUA submissions and amendments. This covers preparedness-focused reviews by the Centers (CBER, CDER, CDRH) and reflects the paperwork time for voluntary pre‑submission engagement.
State/Local Public Health Authority Burdens
State and local public health authorities have specified submission and recordkeeping tasks tied to EUAs: the notice lists 2 hours for certain submissions required under conditions of authorization, 2 hours for requests for Emergency Dispensing Orders, 20 hours for expiration date extension requests to CDER, and 3 hours for recordkeeping in one table entry. These items reflect time public health authorities may need to spend on EUA-related actions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12884 — Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
Previous / Next Documents
Previous: 2025-20770 — Submission for Office of Management and Budget Review; Trafficking Victim Assistance Program Data
The Office on Trafficking in Persons is asking to keep collecting info on how well the Trafficking Victim Assistance Program helps victims of human trafficking. This data helps improve services, report to Congress, and shape future support. If you want to share your thoughts, comments are due by December 24, 2025, with no new costs or big changes planned.
Next: 2025-20772 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; 510(k) Third-Party Review Program
The FDA is asking for public feedback on extending its 510(k) Third-Party Review Program, which lets private experts help review certain medical device applications. This program affects device makers who want faster reviews and keeps paperwork manageable. Comments are due by December 24, 2025, and the program helps speed up device approvals without extra costs to manufacturers.